N/A
Manufactured by AbbVie Inc.
9,899 FDA adverse event reports analyzed
Last updated: 2026-04-15
ATOGEPANT is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by AbbVie Inc.. The most commonly reported adverse reactions for ATOGEPANT include MIGRAINE, DRUG INEFFECTIVE, HEADACHE, NAUSEA, CONSTIPATION. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ATOGEPANT.
Out of 5,787 classified reports for ATOGEPANT:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 9,899 FDA FAERS reports that mention ATOGEPANT. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include MIGRAINE, DRUG INEFFECTIVE, HEADACHE, NAUSEA, CONSTIPATION, FATIGUE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list AbbVie Inc. in connection with ATOGEPANT. Always verify the specific product and NDC with your pharmacist.